• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.

作者信息

Parodis Ioannis, Gomez Alvaro, Emamikia Sharzad, Chatzidionysiou Katerina

机构信息

Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Rheumatology, Karolinska University Hospital, Stockholm, Sweden.

出版信息

Ann Rheum Dis. 2019 Jul;78(7):1006-1007. doi: 10.1136/annrheumdis-2018-214880. Epub 2019 Jan 4.

DOI:10.1136/annrheumdis-2018-214880
PMID:30610063
Abstract
摘要

相似文献

1
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.已有的器官损伤会降低贝利尤单抗在系统性红斑狼疮中的疗效。
Ann Rheum Dis. 2019 Jul;78(7):1006-1007. doi: 10.1136/annrheumdis-2018-214880. Epub 2019 Jan 4.
2
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.贝鲁单抗治疗系统性红斑狼疮后低疾病活动度和临床缓解的预测因素。
Rheumatology (Oxford). 2019 Dec 1;58(12):2170-2176. doi: 10.1093/rheumatology/kez191.
3
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.狼疮低疾病活动状态（LLDAS）可区分系统性红斑狼疮贝鲁单抗 BLISS-52 和 BLISS-76 三期临床试验中的应答者。
Ann Rheum Dis. 2019 May;78(5):629-633. doi: 10.1136/annrheumdis-2018-214427. Epub 2019 Jan 24.
4
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria.使用贝利尤单抗治疗的系统性红斑狼疮患者的结局：基于英伦狼疮评估小组联合狼疮评估标准对五项III期临床试验进行的事后疗效分析
RMD Open. 2025 Apr 23;11(2):e005444. doi: 10.1136/rmdopen-2025-005444.
5
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.接受贝利尤单抗治疗与标准治疗的患者的器官损伤：倾向评分匹配的比较分析。
Ann Rheum Dis. 2019 Mar;78(3):372-379. doi: 10.1136/annrheumdis-2018-214043. Epub 2019 Jan 4.
6
Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.开发和验证一种新的基于证据的狼疮多变量结局评分用于临床试验。
Arthritis Rheumatol. 2018 Sep;70(9):1450-1458. doi: 10.1002/art.40522. Epub 2018 Aug 3.
7
Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.贝利尤单抗治疗系统性红斑狼疮患者的长期安全性及有限的器官损害：一项III期研究的扩展
Rheumatology (Oxford). 2020 Feb 1;59(2):281-291. doi: 10.1093/rheumatology/kez279.
8
Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.日本系统性红斑狼疮患者接受贝利尤单抗治疗后的器官系统改善：一项来自 III 期随机安慰剂对照试验的亚组分析。
Mod Rheumatol. 2020 Mar;30(2):313-320. doi: 10.1080/14397595.2019.1630897. Epub 2019 Jul 4.
9
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus.贝利尤单抗治疗对抗磷脂抗体水平的影响：基于两项系统性红斑狼疮随机安慰剂对照试验的事后分析
Ann Rheum Dis. 2020 Feb;79(2):304-307. doi: 10.1136/annrheumdis-2019-216367. Epub 2019 Nov 11.
10
Belimumab for systemic lupus erythematosus.贝利尤单抗治疗系统性红斑狼疮。
Cochrane Database Syst Rev. 2021 Feb 25;2(2):CD010668. doi: 10.1002/14651858.CD010668.pub2.

引用本文的文献

1
Memory B cells and their transcriptomic profiles associated with belimumab resistance in systemic lupus erythematosus in the maintenance phase.维持期系统性红斑狼疮中与贝利尤单抗耐药相关的记忆B细胞及其转录组图谱。
Front Immunol. 2025 Feb 5;16:1506298. doi: 10.3389/fimmu.2025.1506298. eCollection 2025.
2
Serum IFN-γ Predicts the Therapeutic Effect of Belimumab in Refractory Lupus Nephritis Patients.血清干扰素-γ可预测贝利尤单抗对难治性狼疮性肾炎患者的治疗效果。
Pharmgenomics Pers Med. 2024 Sep 30;17:443-452. doi: 10.2147/PGPM.S476308. eCollection 2024.
3
Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus.
系统性红斑狼疮达标治疗策略的演变概念
Mediterr J Rheumatol. 2024 Jun 30;35(Suppl 2):328-341. doi: 10.31138/mjr.290424.eci. eCollection 2024 Jun.
4
Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab.系统性红斑狼疮肾活动的预测因素：贝利尤单抗四项III期临床试验的事后分析
Rheumatology (Oxford). 2025 Feb 1;64(2):623-631. doi: 10.1093/rheumatology/keae023.
5
B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools.系统性红斑狼疮中的B细胞：新疗法的靶点及监测工具
Front Med (Lausanne). 2022 Aug 30;9:952304. doi: 10.3389/fmed.2022.952304. eCollection 2022.
6
Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus.B细胞和浆细胞亚群的早期变化以及传统血清学标志物作为系统性红斑狼疮中SRI-4治疗反应预测指标的研究
Front Med (Lausanne). 2022 Apr 28;9:852162. doi: 10.3389/fmed.2022.852162. eCollection 2022.
7
EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus.EQ-5D-3L 完全健康状态可区分系统性红斑狼疮临床试验中的药物和安慰剂。
Rheumatology (Oxford). 2021 Oct 2;60(10):4703-4716. doi: 10.1093/rheumatology/keab080.
8
B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice.系统性红斑狼疮的B细胞疗法：从理论依据到临床实践
Front Med (Lausanne). 2020 Jul 9;7:316. doi: 10.3389/fmed.2020.00316. eCollection 2020.
9
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.贝鲁单抗治疗系统性红斑狼疮后低疾病活动度和临床缓解的预测因素。
Rheumatology (Oxford). 2019 Dec 1;58(12):2170-2176. doi: 10.1093/rheumatology/kez191.